His primary areas of investigation include Cancer research, Multiple myeloma, Immunology, Bone marrow and Protein kinase B. The Cancer research study combines topics in areas such as Imatinib mesylate, Transfection, GAB2, PI3K/AKT/mTOR pathway and Cytotoxicity. His Multiple myeloma research integrates issues from Pharmacology and Proteasome.
His studies in Immunology integrate themes in fields like Natural killer cell, Peripheral blood mononuclear cell, Haematopoiesis and Osteoclast. His research in Bone marrow intersects with topics in Cytokine, Stromal cell and Antibody-dependent cell-mediated cytotoxicity. His work carried out in the field of Thalidomide brings together such families of science as Immune system and Cell killing.
Klaus Podar mainly focuses on Cancer research, Multiple myeloma, Bortezomib, Stromal cell and Cell growth. His Cancer research research is multidisciplinary, incorporating elements of Immunology, Bone marrow and Apoptosis. Klaus Podar has included themes like Peripheral blood mononuclear cell, Endocrinology, Cell killing and CD40 in his Bone marrow study.
Many of his research projects under Multiple myeloma are closely connected to Drug resistance with Drug resistance, tying the diverse disciplines of science together. His Bortezomib study integrates concerns from other disciplines, such as Proteasome inhibitor, Proteasome and Downregulation and upregulation. His Cell growth research incorporates themes from Cell and Protein kinase B, Signal transduction, Kinase, Cell biology.
Klaus Podar spends much of his time researching Cancer research, Multiple myeloma, Bortezomib, Bone marrow and Cell growth. Klaus Podar has researched Cancer research in several fields, including Apoptosis, Signal transduction and Cell adhesion. In the field of Multiple myeloma, his study on Lenalidomide overlaps with subjects such as Drug resistance.
His Bortezomib research is within the category of Immunology. His Bone marrow study incorporates themes from Pharmacology and MAPK/ERK pathway. The concepts of his Cell growth study are interwoven with issues in Kinase, Cell biology and Janus kinase inhibitor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Faith E. Davies;Noopur Raje;Noopur Raje;Noopur Raje;Teru Hideshima;Teru Hideshima;Teru Hideshima;Suzanne Lentzsch;Suzanne Lentzsch;Suzanne Lentzsch.
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.
D Gupta;S P Treon;Y Shima;T Hideshima.
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
Dharminder Chauhan;Laurence Catley;Guilan Li;Klaus Podar.
Cancer Cell (2005)
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
Teru Hideshima;Constantine Mitsiades;Masaharu Akiyama;Toshiaki Hayashi.
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Teru Hideshima;Laurence Catley;Hiroshi Yasui;Kenji Ishitsuka.
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
Klaus Podar;Yu-Tzu Tai;Faith E. Davies;Suzanne Lentzsch.
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu
Yu Tzu Tai;Myles Dillon;Weihua Song;Merav Leiba.
Critical role for Gab2 in transformation by BCR/ABL
Martin Sattler;M.Golam Mohi;Yuri B Pride;Laura R Quinnan.
Cancer Cell (2002)
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.
Klaus Podar;Kenneth C. Anderson.
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.
Toshiaki Hayashi;Teru Hideshima;Masaharu Akiyama;Klaus Podar.
British Journal of Haematology (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: